Leukotriene receptor antagonist used for bronchial asthama is
**Core Concept**
The question tests the student's knowledge of pharmacological management of bronchial asthma, specifically the role of **leukotriene receptor antagonists**. These drugs work by blocking the action of **leukotrienes**, which are inflammatory mediators involved in the pathogenesis of asthma.
**Why the Correct Answer is Right**
The correct answer is a drug that antagonizes the **leukotriene receptors**, thereby reducing inflammation and preventing bronchoconstriction in asthma patients. This class of drugs includes **montelukast** and **zafirlukast**, which are commonly used in the management of bronchial asthma.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not specify a leukotriene receptor antagonist.
**Option B:** This option is incorrect because it is not a recognized leukotriene receptor antagonist.
**Option C:** This option is incorrect as it is not relevant to the management of bronchial asthma with leukotriene receptor antagonists.
**Clinical Pearl / High-Yield Fact**
A key point to remember is that **leukotriene receptor antagonists** are useful in patients who cannot tolerate **inhaled corticosteroids** or have mild asthma. They can also be used as add-on therapy in patients not adequately controlled by **inhaled corticosteroids** alone.
**Correct Answer:** D. Montelukast.